File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s40364-020-00202-7
- Scopus: eid_2-s2.0-85087615525
- WOS: WOS:000546151100001
Supplementary
- Citations:
- Appears in Collections:
Article: Role of DNA repair defects in predicting immunotherapy response
Title | Role of DNA repair defects in predicting immunotherapy response |
---|---|
Authors | |
Keywords | Biomarkers DNA damage response Immune checkpoint blockade Immunotherapy |
Issue Date | 2020 |
Citation | Biomarker Research, 2020, v. 8, n. 1, article no. 23 How to Cite? |
Abstract | Defect in DNA damage response (DDR) is a common feature of cancer cells, which regulates tumor growth and therapeutic response. Recently, the approval of immune checkpoint blockade (ICB) for tumors with defective mismatch repair has paved the way for investigating the role of other DDR defects in sensitizing cancer to ICB therapy. Despite great progress in understanding DDR pathways, the mechanisms that link DDR defects and ICB response remain incompletely understood. Further, the clinical activity of ICB in patients with DDR defective tumors has not been well described. Here, we discuss recent studies demonstrating that biomarkers in DDR pathways may serve as potential predictors to guide the selection of patients for ICB therapy. A better understanding of the relationship between deficiency in DDR and response to ICB would facilitate efforts in optimizing the efficacy of immunotherapy. |
Persistent Identifier | http://hdl.handle.net/10722/313999 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang, Jing | - |
dc.contributor.author | Shih, David J.H. | - |
dc.contributor.author | Lin, Shiaw Yih | - |
dc.date.accessioned | 2022-07-06T11:28:48Z | - |
dc.date.available | 2022-07-06T11:28:48Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Biomarker Research, 2020, v. 8, n. 1, article no. 23 | - |
dc.identifier.uri | http://hdl.handle.net/10722/313999 | - |
dc.description.abstract | Defect in DNA damage response (DDR) is a common feature of cancer cells, which regulates tumor growth and therapeutic response. Recently, the approval of immune checkpoint blockade (ICB) for tumors with defective mismatch repair has paved the way for investigating the role of other DDR defects in sensitizing cancer to ICB therapy. Despite great progress in understanding DDR pathways, the mechanisms that link DDR defects and ICB response remain incompletely understood. Further, the clinical activity of ICB in patients with DDR defective tumors has not been well described. Here, we discuss recent studies demonstrating that biomarkers in DDR pathways may serve as potential predictors to guide the selection of patients for ICB therapy. A better understanding of the relationship between deficiency in DDR and response to ICB would facilitate efforts in optimizing the efficacy of immunotherapy. | - |
dc.language | eng | - |
dc.relation.ispartof | Biomarker Research | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Biomarkers | - |
dc.subject | DNA damage response | - |
dc.subject | Immune checkpoint blockade | - |
dc.subject | Immunotherapy | - |
dc.title | Role of DNA repair defects in predicting immunotherapy response | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1186/s40364-020-00202-7 | - |
dc.identifier.scopus | eid_2-s2.0-85087615525 | - |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | article no. 23 | - |
dc.identifier.epage | article no. 23 | - |
dc.identifier.eissn | 2050-7771 | - |
dc.identifier.isi | WOS:000546151100001 | - |